Sanofi announced the completion of its acquisition of Blueprint Medicines Corporation, finalizing the transaction that was initially announced on June 2, 2025. This acquisition integrates Blueprint's commercialized medicine, AYVAKIT (avapritinib), and its promising pipeline into Sanofi's portfolio.
The acquisition includes AYVAKIT, approved in the U.S. and the EU for systemic mastocytosis, as well as pipeline assets such as elenestinib and BLU-808. This strategic move is expected to expand Sanofi's presence in rare immunological diseases and enhance its early-stage immunology pipeline.
Under the terms of the merger agreement, Blueprint shareholders received $129.00 per share in cash. Additionally, shareholders received one non-tradeable contingent value right (CVR) per share, which provides for two potential milestone payments of $2 and $4 per CVR upon the achievement of future development and regulatory milestones for BLU-808.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.